PFHxS: A Six-Carbon Sulfonate With a Long Human Half-Life
Perfluorohexane sulfonate (PFHxS) occupies a middle position in the perfluoroalkyl sulfonate family — longer than PFBS (C4) and shorter than PFOS (C8). Its human elimination half-life of approximately eight years places it closer to PFOS than to short-chain sulfonates, meaning chronic exposure from drinking water or diet can produce substantial and sustained serum accumulation. This pharmacokinetic profile has made PFHxS one of the more closely scrutinized PFAS compounds in recent epidemiological literature, particularly in studies focused on children and pregnant women.
PFHxS was designated a CERCLA hazardous substance by the U.S. EPA in 2024 and was assigned an individual MCL of 10 ppt in the final PFAS drinking water rule. The EPA’s hazard assessment cites thyroid hormone disruption and developmental neurotoxicity as the key endpoints of concern. Internationally, PFHxS is restricted under the Stockholm Convention as a persistent organic pollutant, with global production and use now curtailed in signatory nations.
Thyroid Hormone Effects: Cross-Sectional and Prospective Evidence
The strongest epidemiological signal for PFHxS health effects involves thyroid hormone disruption. Multiple cross-sectional studies in adult and pediatric populations have reported inverse associations between serum PFHxS and free T4 or T3 levels. Thyroid hormones are critical regulators of metabolic rate, cardiovascular function, and — critically for developmental neurotoxicology — fetal and infant brain maturation. Even modest perturbations in maternal thyroid function during the first trimester have been linked in prospective cohorts to measurable reductions in offspring cognitive performance.
A particularly robust dataset comes from the Faroese cohort studies, which have followed children from birth through adolescence and measured PFAS alongside thyroid hormones, immune markers, and neurodevelopmental outcomes. PFHxS, alongside PFOA, PFOS, and PFNA, was associated with thyroid hormone alterations that persisted at follow-up assessments. The dose-response relationships in these studies support a causal interpretation, though the mixture exposure context complicates attribution to any single compound.
ADHD-Like Behavioral Outcomes: Epidemiological Findings
Beyond thyroid-mediated effects, epidemiological studies have reported associations between childhood PFHxS exposure and ADHD-like behavioral phenotypes, including inattention, hyperactivity, and impulsivity as measured by standardized rating scales. A 2023 meta-analysis pooling data from seven prospective birth cohorts found that PFHxS was among the compounds most consistently associated with ADHD symptoms in children aged 5–12, independent of co-occurring PFOS and PFOA exposures.
The mechanistic plausibility for neurological effects is supported by in vitro and animal data showing that PFHxS can cross the blood-brain barrier, alter dopaminergic signaling in prefrontal cortex circuits, and disrupt hippocampal synaptic plasticity at concentrations achievable in exposed human populations. Rodent studies have reported sex-specific behavioral effects, with male offspring showing more pronounced hyperactivity after gestational exposure — a pattern echoed in some human epidemiological findings.
Implications for Drinking Water Standards and Monitoring
The epidemiological evidence for PFHxS neurological effects has directly informed the EPA’s decision to set a standalone MCL of 10 ppt rather than relying solely on the Hazard Index. This conservative stance reflects the recognition that neurological development endpoints — particularly those with lifelong implications — warrant lower tolerance for uncertainty than reversible adult health outcomes. Regulators in several European countries are conducting parallel reviews of PFHxS under the EU Drinking Water Directive’s broad PFAS sum parameter.
For public health practitioners and risk communicators, the PFHxS evidence base illustrates a recurring pattern in PFAS science: compounds initially introduced as safer alternatives have, upon accumulation of evidence, revealed distinct and sometimes severe toxicological profiles. The long half-life of PFHxS means that historical exposures from now-discontinued sources continue to contribute to current serum levels in adults, complicating exposure-response analyses and highlighting the need for longitudinal biomonitoring programs.